// Auto-generated - do not edit
export const substanceName = "Triazolam";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Triazolam.md","displayName":"DrugBank","size":18016},{"id":"protestkit","fileName":"PROTESTKIT - Triazolam.json","displayName":"Protest Kit","size":3825},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Triazolam.md","displayName":"TripSit Factsheets","size":635},{"id":"wikipedia","fileName":"WIKIPEDIA - Triazolam.md","displayName":"Wikipedia","size":9167}];
export const contents: Record<string, string> = {
  "drugbank": `# Triazolam
*Source: https://go.drugbank.com/drugs/DB00897*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring.

### Background

Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

### Indication

For the short-term treatment of insomnia.

### Pharmacodynamics

A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Absorption

Bioavailability is 44% (oral) and 53% (sublingual).

### Metabolism

Hepatic. Small amounts of unmetabolized triazolam appear in the urine.
Hover over products below to view reaction partners
Triazolam
4-hydroxytriazolam
1'-hydroxytriazolam

### Half-life

1.5-5.5 hours

### Toxicity

Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Triazolam is combined with 1,2-Benzodiazepine.
Abacavir
Triazolam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir
The serum concentration of Triazolam can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Triazolam can be increased when combined with Abatacept.
Acalabrutinib
The metabolism of Triazolam can be decreased when combined with Acalabrutinib.

### Food Interactions

Avoid alcohol. Ingesting alcohol may increase the risk of complex behaviors like sleep-driving, which the patient does not remember.
Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of triazolam, which increases the serum concentration of triazolam.

## Chemical Information

**DrugBank ID:** DB00897

**Synonyms:** Triazolam
Triazolamum

**Chemical Formula:** C
17
H
12
Cl
2
N
4

**SMILES:** CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12

**Weight:** Average: 343.21
Monoisotopic: 342.043901818

**IUPAC Name:** 12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

7

### Phase 2

2

### Phase 3

2

### Phase 4

1

### Therapeutic Categories

Benzodiazepines and benzodiazepine
derivatives

### Summary

Triazolam
is a benzodiazepine used for short term treatment of insomnia.

### Brand Names

Halcion

### Generic Name

Triazolam

### DrugBank Accession Number

DB00897

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Triazolam (DB00897)
×
Close

### External IDs

DEA No. 2887
N05CD05
U 33030

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Insomnia
••••••••••••
Create Account
Create Account

### Associated Therapies

Sedation

### Mechanism of action

Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA
A
) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans
U
Translocator protein
modulator
Humans

### Route of elimination

Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion.

### Product Images

Previous
Next

### International/Other Brands

Apo-Triazo (Apotex)
/
Arring (YungShin)
/
Asasion (Choseido Pharmaceutical Co., Ltd)
/
Ascomarna (Nisshin Seiyaku K.K)
/
Songar (Valeas S.p.A.)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Halcion
Tablet
0.125 mg
Oral
Pfizer Italia S.R.L.
1980-12-31
2006-08-02
Canada
Halcion
Tablet
.125 mg/1
Oral
Pharmacia &amp; Upjohn Company LLC
2006-01-19
2006-01-19
US
Halcion
Tablet
0.25 mg
Oral
Pfizer Italia S.R.L.
1978-12-31
2007-05-29
Canada
Halcion
Tablet
0.25 mg/1
Oral
Physicians Total Care, Inc.
1982-11-15
2012-06-30
US
Halcion
Tablet
0.25 mg/1
Oral
Pharmacia &amp; Upjohn Company LLC
1982-11-15
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Alti-triazolam Tab 0.125mg
Tablet
.125 mg / tab
Oral
Altimed Pharma Inc.
1987-12-31
2001-09-05
Canada
Alti-triazolam Tab 0.25mg
Tablet
.25 mg / tab
Oral
Altimed Pharma Inc.
1987-12-31
2001-09-05
Canada
Mylan-triazolam
Tablet
0.125 mg
Oral
Mylan Pharmaceuticals Inc.
1992-12-31
2011-03-04
Canada
Mylan-triazolam
Tablet
0.25 mg
Oral
Mylan Pharmaceuticals Inc.
1992-12-31
2011-03-04
Canada
Novo-triolam Tab 0.125mg
Tablet
.125 mg
Oral
Novopharm Limited
1990-12-31
2005-08-10
Canada

### ATC Codes

N05CD05 — Triazolam
N05CD — Benzodiazepine derivatives
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Adjuvants, Anesthesia
Agents Causing Muscle Toxicity
Anti-Anxiety Agents
Benzazepines
Benzodiazepine hypnotics and sedatives
Benzodiazepines and benzodiazepine derivatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 CYP3A5 Substrates
Cytochrome P-450 CYP3A7 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Drugs that are Mainly Renally Excreted
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Hypnotics and Sedatives
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents
Triazolobenzodiazepines

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,2,4-triazolo[4,3-a][1,4]benzodiazepines
Alternative Parents
Chlorobenzenes
/
Aryl chlorides
/
Triazoles
/
Heteroaromatic compounds
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Hydrocarbon derivatives
Substituents
1,2,4-triazole
/
1,2,4-triazolo[4,3-a][1,4]benzodiazepine
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Azole
/
Benzenoid
/
Chlorobenzene
/
Halobenzene
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
triazolobenzodiazepine (
CHEBI:9674
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,2,4-triazolo[4,3-a][1,4]benzodiazepines

### Alternative Parents

Chlorobenzenes
/
Aryl chlorides
/
Triazoles
/
Heteroaromatic compounds
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Hydrocarbon derivatives

### Substituents

1,2,4-triazole
/
1,2,4-triazolo[4,3-a][1,4]benzodiazepine
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Azole
/
Benzenoid
/
Chlorobenzene
/
Halobenzene

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

triazolobenzodiazepine (
CHEBI:9674
)

### Affected organisms

Humans and other mammals

### UNII

1HM943223R

### CAS number

28911-01-5

### InChI Key

JOFWLTCLBGQGBO-UHFFFAOYSA-N

### InChI

InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

### General References

Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [
Article
]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [
Article
]
Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [
Article
]
Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [
Article
]
Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek]. Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. [
Article
]

### External Links

Human Metabolome Database
HMDB0015034
KEGG Drug
D00387
PubChem Compound
5556
PubChem Substance
46509147
ChemSpider
5355
BindingDB
50001765
RxNav
10767
ChEBI
9674
ChEMBL
CHEMBL646
ZINC
ZINC000000002212
Therapeutic Targets Database
DAP000244
PharmGKB
PA451753
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Triazolam

### Human Metabolome Database

HMDB0015034

### KEGG Drug

D00387

### PubChem Compound

5556

### PubChem Substance

46509147

### ChemSpider

5355

### BindingDB

50001765

### RxNav

10767

### ChEBI

9674

### ChEMBL

CHEMBL646

### ZINC

ZINC000000002212

### Therapeutic Targets Database

DAP000244

### PharmGKB

PA451753

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### PDRhealth

PDRhealth Drug Page

### Wikipedia

Triazolam

### MSDS

Download
(5.44 KB)

### Manufacturers

Pharmacia and upjohn co
Alphapharm party ltd
Roxane laboratories inc
Watson laboratories inc

### Packagers

Alphapharm Party Ltd.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Corepharma LLC
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Genpharm LP
Greenstone LLC
H.J. Harkins Co. Inc.
Keltman Pharmaceuticals Inc.
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Pharmacia Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Rebel Distributors Corp.
Roxane Labs
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy

### Dosage Forms

Form
Route
Strength
Tablet
Oral
.125 mg / tab
Tablet
Oral
.25 mg / tab
Tablet
Oral
.125 mg/1
Tablet
Oral
0.5 MG
Tablet
Oral
125 MICROGRAMMI
Tablet
Oral
250 MICROGRAMMI
Tablet
Oral
Tablet
Oral
0.125 mg
Tablet
Oral
.125 mg
Tablet
Oral
.25 mg
Capsule
Oral
0.25 MG
Capsule
Oral
0125 MG
Solution / drops
Oral
Tablet
Oral
0.1250 mg
Tablet
Oral
0.125 mg/1
Tablet
Oral
0.25 mg/1
Tablet
Oral
0.25 mg
Tablet
Oral
0125 MG

### Prices

Unit description
Cost
Unit
Halcion 10 0.25 mg tablet Bottle
21.0USD
bottle
Triazolam 10 0.125 mg tablet Bottle
6.33USD
bottle
Triazolam 10 0.25 mg tablet Bottle
6.0USD
bottle
Halcion 0.25 mg tablet
1.99USD
tablet
Halcion 0.125 mg tablet
1.37USD
tablet
Triazolam 0.25 mg tablet
0.67USD
tablet
Triazolam 0.125 mg tablet
0.65USD
tablet
Apo-Triazo 0.25 mg Tablet
0.22USD
tablet
Mylan-Triazolam 0.25 mg Tablet
0.22USD
tablet
Apo-Triazo 0.125 mg Tablet
0.12USD
tablet
Mylan-Triazolam 0.125 mg Tablet
0.12USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
233-235 °C
Not Available
water solubility
4.53 mg/L
Not Available
logP
2.42
BIOBYTE (1995)
logS
-4.08
ADME Research, USCD

### Predicted Properties

Property
Value
Source
Water Solubility
0.0183 mg/mL
ALOGPS
logP
2.94
ALOGPS
logP
3.63
Chemaxon
logS
-4.3
ALOGPS
pKa (Strongest Acidic)
17.98
Chemaxon
pKa (Strongest Basic)
4.26
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
43.07 Å
2
Chemaxon
Rotatable Bond Count
1
Chemaxon
Refractivity
103.68 m
3
·mol
-1
Chemaxon
Polarizability
34.19 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
1.0
Blood Brain Barrier
+
0.9719
Caco-2 permeable
+
0.886
P-glycoprotein substrate
Non-substrate
0.5252
P-glycoprotein inhibitor I
Non-inhibitor
0.6788
P-glycoprotein inhibitor II
Inhibitor
0.8331
Renal organic cation transporter
Inhibitor
0.7628
CYP450 2C9 substrate
Non-substrate
0.7898
CYP450 2D6 substrate
Non-substrate
0.9208
CYP450 3A4 substrate
Substrate
0.751
CYP450 1A2 substrate
Inhibitor
0.8598
CYP450 2C9 inhibitor
Inhibitor
0.815
CYP450 2D6 inhibitor
Non-inhibitor
0.8226
CYP450 2C19 inhibitor
Inhibitor
0.7117
CYP450 3A4 inhibitor
Non-inhibitor
0.5596
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.9088
Ames test
Non AMES toxic
0.9132
Carcinogenicity
Non-carcinogens
0.6714
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
1.9971 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9638
hERG inhibition (predictor II)
Non-inhibitor
0.8806
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0006-8089000000-80a2c04b55ba4ec57f7d
Mass Spectrum (Electron Ionization)
MS
splash10-0imr-4954000000-75bcea16a1182103168f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-439a372277eb9d7b84c5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-9a1a20ce1a0982eb608a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-ba834846753af69ac024
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-c2d9a1315e70661774c4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-01ri-0096000000-e7da2771e1cfa7c211eb
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0f9x-3192000000-a6123eaa7899f05d0158
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
174.3785356
predicted
DarkChem Lite v0.1.0
[M-H]-
171.45076
predicted
DeepCCS 1.0 (2019)
[M+H]+
175.0905356
predicted
DarkChem Lite v0.1.0
[M+H]+
173.80876
predicted
DeepCCS 1.0 (2019)
[M+Na]+
174.9081356
predicted
DarkChem Lite v0.1.0
[M+Na]+
180.69753
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### Curator comments

This enzyme relationship is supported by 1 in vitro study available in the literature.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)

### Specific Function

estrogen 16-alpha-hydroxylase activity

### Gene Name

CYP3A5

### Uniprot ID

P20815

### Uniprot Name

Cytochrome P450 3A5

### Molecular Weight

57108.065 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/triazolam",
  "experiencesUrl": "https://www.reddit.com/search/?q=Triazolam",
  "name": "Triazolam",
  "aliases": [
    "halcion"
  ],
  "aliasesStr": "halcion",
  "summary": "An uncommon and very short acting benzodiazepine. Sedating and hypnotic, and may induce amnesia and lowered inhibitions at high doses.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Benzodiazepines"
    ],
    "psychoactive": [
      "Depressant"
    ]
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "0.125-0.25mg"
        },
        {
          "name": "Common",
          "value": "0.25-0.5mg"
        },
        {
          "name": "Strong",
          "value": "0.5-1.5mg+"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.33 hours"
        },
        {
          "name": "Duration",
          "value": "4.0 - 7.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 6.0 hours"
        }
      ]
    },
    {
      "name": "Insufflated",
      "duration": [
        {
          "name": "Duration",
          "value": "3.0 - 5.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 6.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cocaine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DXM",
      "status": "Caution"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MAOIs",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MMC class",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Anxiolytic, but primarily sedative or hypnotic.",
  "categorized_effects": {
    "Physical effects": [
      "but primarily sedative or hypnotic."
    ],
    "Mental effects": [
      "Anxiolytic"
    ],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Triazolam
*Source: TripSit Factsheets (tripsit.me)*

## Summary

An uncommon and very short-acting benzodiazepine. Sedating and hypnotic and may induce amnesia and lowered inhibitions at higher doses.

## Classification
- **Categories:** benzodiazepine, habit-forming, depressant
- **Also known as:** halcion

## Dosage

### Oral
- **Common:** 0.25-0.5mg
- **Light:** 0.125-0.25mg
- **Strong:** 0.5-1.5mg+

## Duration
- **Onset:** 10-20 minutes
- **Duration:** hours
- **After Effects:** 1-6 hours

## Effects
- Anxiolytic
- primarily sedative and hypnotic effects

## Additional Information
- **Avoid:** All other CNS depressants.
`,
  "wikipedia": `# Triazolam
*Source: https://en.wikipedia.org/wiki/Triazolam*

Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.
Triazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.

## Medical uses

Triazolam is usually used for short-term treatment of acute insomnia and circadian rhythm sleep disorders, including jet lag. It is an ideal benzodiazepine for this use because of its fast onset of action and short half-life. It puts a person to sleep for about 1.5 hours, allowing its user to avoid morning drowsiness. Triazolam is also sometimes used as an adjuvant in medical procedures requiring anesthesia or to reduce anxiety during brief events, such as MRI scans and nonsurgical dental procedures. Triazolam is ineffective in maintaining sleep due to its short half-life, with quazepam showing superiority.
Triazolam is frequently prescribed as a sleep aid for passengers travelling on short- to medium-duration flights. If this use is contemplated, the user avoiding the consumption of alcohol is especially important, as is trying a ground-based "rehearsal" of the medication to ensure that the side effects and potency of this medication are understood by the user prior to using it in a relatively more public environment (as disinhibition can be a common side effect, with potentially severe consequences). Triazolam causes anterograde amnesia, which is why so many dentists administer it to patients undergoing even minor dental procedures. This practice is known as sedation dentistry.

## Side effects

Adverse drug reactions associated with the use of triazolam include:

Relatively common  (>1% of patients): somnolence, dizziness, lightheadedness, coordination problems
Less common  (0.9% to 0.5% of patients): euphoria, tachycardia, fatigue, delirium, memory impairment, cramps/pain, depression, visual disturbances
Rare (<0.5% of patients): constipation, taste alteration, diarrhea, dry mouth, dermatitis/allergy, abnormal dreams or nightmares, insomnia (paradoxical), paresthesia, tinnitus, dysesthesia, weakness, nasal/sinus congestion
Triazolam, although a short-acting benzodiazepine, may cause residual impairment into the next day, especially the next morning. A meta-analysis demonstrated that residual "hangover" effects after nighttime administration of triazolam such as sleepiness, psychomotor impairment, and diminished cognitive functions may persist into the next day, which may impair the ability of users to drive safely and increase risks of falls and hip fractures. Confusion and amnesia have been reported. Triazolam use can shift the circadian cycle.
In September 2020, the US Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.

### Tolerance, dependence, and withdrawal

A review of the literature found that long-term use of benzodiazepines, including triazolam, is associated with drug tolerance, drug dependence, rebound insomnia, and CNS-related adverse effects. Benzodiazepine hypnotics should be used at their lowest possible dose and for a short period of time. Nonpharmacological treatment options were found to yield sustained improvements in sleep quality.  A worsening of insomnia (rebound insomnia) compared to baseline may occur after discontinuation of triazolam, even following short-term, single-dose therapy.
Other withdrawal symptoms can range from mild unpleasant feelings to a major withdrawal syndrome, including stomach cramps, vomiting, muscle cramps, sweating, tremor, and in rare cases, convulsions.

### Contraindications

Benzodiazepines require special precautions if used in the elderly, during pregnancy, in children, in alcoholics, or in other drug-dependent individuals and individuals with comorbid psychiatric disorders. Triazolam belongs to the Pregnancy Category X of the FDA. It is known to have the potential to cause birth defects.

### Elderly

Triazolam, similar to other benzodiazepines and nonbenzodiazepines, causes impairments in body balance and standing steadiness. Falls and hip fractures are frequently reported, especially by elderly persons. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments. Daytime withdrawal effects can occur.
An extensive review of the medical literature regarding the management of insomnia and the elderly found considerable evidence of the effectiveness and durability of nondrug treatments for insomnia in adults of all ages and that these interventions are underused. Compared with the benzodiazepines including triazolam, the nonbenzodiazepine sedative-hypnotics appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. Newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment, anterograde amnesia, daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. One study found no evidence of sustained hypnotic efficacy throughout the 9 weeks of treatment for triazolam.
In addition, the effectiveness and safety of long-term use of these agents remain to be determined. More research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.

## Interactions

Ketoconazole and itraconazole have a profound effect on the pharmacokinetics of triazolam, leading to greatly enhanced effects. Anxiety, tremor, and depression have been documented in a case report following administration of nitrazepam and triazolam. Following administration of erythromycin, repetitive hallucinations and abnormal bodily sensations developed. The patient had, however, acute pneumonia, and kidney failure. Co-administration of benzodiazepine drugs at therapeutic doses with erythromycin may cause serious psychotic symptoms, especially in those with other physical complications. Caffeine reduces the effectiveness of triazolam. Other important interactions include cimetidine, diltiazem, fluconazole, grapefruit juice, isoniazid, itraconazole, nefazodone, rifampicin, ritonavir, and troleandomycin. Triazolam should not be administered to patients on efavirenz/emtricitabine/tenofovir (Atripla).

## Overdose

Symptoms of an overdose include:

Coma
Hypoventilation (respiratory depression)
Somnolence (drowsiness)
Slurred speech
Seizures
Death can occur from triazolam overdose, but is more likely to occur in combination with other depressant drugs such as opioids, alcohol, or tricyclic antidepressants.

## Pharmacology

Like other benzodiazepines, triazolam enhances the inhibitory effects of the neurotransmitter GABA by binding to the allosteric benzodiazepine receptor on GABAA receptor complexes.
Triazolam is short-acting, is lipophilic, and is metabolized hepatically via oxidative pathways. Triazolam produces one short-acting active metabolite, alpha-hydroxytriazolam, which is suspected to be of minor clinical significance. The half-life of triazolam is only 2 hours making it a very short acting benzodiazepine drug. It has anticonvulsant effects on brain function.

## Society and culture

### Recreational use

Triazolam, like other benzodiazepines, is susceptible to misuse and abuse. Its rapid onset of action and short half-life contribute to its abuse potential, but its relative obscurity compared to other fast-acting benzodiazepines (such as alprazolam or lorazepam) prevent its abuse from becoming particularly commonplace. Likewise, because it is not prescribed as often or as readily as alprazolam or lorazepam, there is less triazolam available to be diverted for recreational use.

### Legal status

Its use at low doses has been deemed acceptable by the US FDA and in several other countries.
Triazolam is a Schedule IV drug under the Convention on Psychotropic Substances  and the US Controlled Substances Act.

### Brand names

The drug is marketed in English-speaking countries under the brand names Apo-Triazo, Halcion, Hypam, and Trilam. Other names include 2'-chloroxanax, chloroxanax, triclazolam, and chlorotriazolam.

== References ==
`,
};
